Iradimed Corp (NASDAQ:IRMD) VP Sells $20,060.00 in Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 1,000 shares of Iradimed stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $20.06, for a total transaction of $20,060.00. Following the transaction, the vice president now directly owns 2,368 shares in the company, valued at $47,502.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Brent Johnson also recently made the following trade(s):

  • On Wednesday, June 12th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $20.57, for a total transaction of $61,710.00.
  • On Friday, June 7th, Brent Johnson sold 1,000 shares of Iradimed stock. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00.
  • On Thursday, May 23rd, Brent Johnson sold 4,000 shares of Iradimed stock. The shares were sold at an average price of $21.78, for a total transaction of $87,120.00.
  • On Monday, May 20th, Brent Johnson sold 2,000 shares of Iradimed stock. The shares were sold at an average price of $22.53, for a total transaction of $45,060.00.
  • On Friday, May 17th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $21.83, for a total transaction of $65,490.00.

Shares of IRMD traded up $0.04 during mid-day trading on Wednesday, reaching $20.98. 25,741 shares of the stock traded hands, compared to its average volume of 62,279. The firm has a market capitalization of $233.63 million, a P/E ratio of 48.79 and a beta of 1.78. Iradimed Corp has a 12-month low of $18.40 and a 12-month high of $38.78. The company has a quick ratio of 8.63, a current ratio of 9.48 and a debt-to-equity ratio of 0.06.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.11. The company had revenue of $8.44 million for the quarter, compared to analyst estimates of $8.38 million. Iradimed had a net margin of 23.00% and a return on equity of 13.98%. Equities analysts expect that Iradimed Corp will post 0.64 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on IRMD shares. BidaskClub lowered shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Tuesday, May 7th. Finally, ValuEngine lowered shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Iradimed has an average rating of “Buy” and a consensus target price of $31.50.

Several institutional investors and hedge funds have recently bought and sold shares of IRMD. Bank of New York Mellon Corp raised its stake in shares of Iradimed by 36.1% during the third quarter. Bank of New York Mellon Corp now owns 30,749 shares of the medical equipment provider’s stock valued at $1,142,000 after purchasing an additional 8,161 shares during the period. Vanguard Group Inc. increased its stake in shares of Iradimed by 19.7% in the third quarter. Vanguard Group Inc. now owns 250,298 shares of the medical equipment provider’s stock worth $9,298,000 after buying an additional 41,184 shares during the last quarter. Strs Ohio increased its stake in shares of Iradimed by 14.5% in the fourth quarter. Strs Ohio now owns 18,700 shares of the medical equipment provider’s stock worth $457,000 after buying an additional 2,367 shares during the last quarter. Dupont Capital Management Corp bought a new stake in shares of Iradimed in the fourth quarter worth $364,000. Finally, Acadian Asset Management LLC increased its stake in shares of Iradimed by 500.7% in the fourth quarter. Acadian Asset Management LLC now owns 26,844 shares of the medical equipment provider’s stock worth $657,000 after buying an additional 22,375 shares during the last quarter. Institutional investors own 23.53% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Iradimed Corp (NASDAQ:IRMD) VP Sells $20,060.00 in Stock” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2019/06/12/iradimed-corp-nasdaqirmd-vp-sells-20060-00-in-stock.html.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Further Reading: What is a blue-chip stock?

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit